Evidence for estradiol promotion of neoplastic lesions in the rat vagina after initiation with N-methyl-N-nitrosourea

Effects of Continuous Estradiol Administration by Polydimethylsiloxane and Paraffin Implants on Serum Hormone Levels and Uterine Responses

Since tonic elevated estrogen levels are associated with toxic responses, including tumor promotion, we investigated the effects of continuous estradiol (E2) administration by paraffin or polydimethylsiloxane (Silastic) implants on pituitary and uterine responses. Ovariectomized (OVEX) Sprague-Dawley rats implanted with low-dose (P1) or high-dose (P2) paraffin pellets showed initial high serum E2 levels that decayed rapidly. Silastic implants provided more constant pharmacological serum E2 levels during the 14 days of exposure. Rising serum LH and FSH levels in OVEX controls were suppressed by all E2 implants. Serum prolactin levels, low in OVEX controls, rose after implantation (P1 and P2) but decayed to control values by 14 days. Prolactin induced by pharmacological E2 levels initially rose, dropped by 72 hours, but again rose at later times. Uterine weight, low in OVEX controls, was increased by all implants. At later times, paraffin implants did not appear to release significant amounts of E2. However, removal of P2 implants from donors followed by transfer to new recipients stimulated uterine growth in recipients. All implants increased uterine DNA and RNA levels and the RNA/DNA ratio during the first 24–48 hours, followed by maintenance of elevated values. Poly(A)-containing RNA, isolated by oligo(dT) cellulose chromatography, comprised a constant percentage of RNA at all hormone levels and treatment times, suggesting a coupling of total RNA and poly(A)-containing RNA accumulation. Results are discussed in relation to the carcinogenic properties of estrogens, known to be correlated with continuous exposure to elevated estrogen levels.

Induction or suppression of SV40 amplification by genotoxic carcinogens, non-genotoxic carcinogens or tumor promoters

Carcinogens are generally classified into two groups: genotoxic and non-genotoxic. As the final product of genotoxic and non-genotoxic carcinogens is the same, i.e., a clone of genetically altered cells, it could be possible that non-genotoxic carcinogens may yield genotoxic events as a secondary result of cell toxicity having led to mitogenesis/cellular proliferation, or that genetic alterations are induced that are normally neglected in genotoxicity tests. A genetic effect with possible relevance for the ultimate mechanism of carcinogenicity is the amplification of oncogenes. In the present experiments, amplification of SV40-virus DNA in transformed CO631-cells has been measured. In this system, two genotoxic carcinogens (positive control), two non-carcinogens (negative control), and eight non-genotoxic carcinogens have been tested. With the exception of testosterone and BVDU, all substances were tested when given alone. Testosterone and BVDU were tested in combination with either MTX or AMP in the presence or absence of S9-mix. The genotoxic carcinogens TEM and 4-NQO as well as the tumor promoters TPA, coumarin, mezerein and chrysarobin were able to induce SV40 amplification when given alone. The same was for acetamide and thioacetamide. The non-carcinogens acetone and dimethylformamide were ineffective. In case of testosterone, a co-amplification effect was seen in the absence of S9-mix, and an anti-amplification effect in presence of S9-mix. The anti-recombinogen BVDU reduced the SV40 amplification effect of AMP in experiments without addition of S9-mix. In the presence of activating S9-mix, this substance was effective at lower concentrations than without S9-mix, and showed an enhanced anti-amplification effect. Similar effects of testosterone and BVDU had been observed before in respect to stimulation or suppression of recombination. These results can be used as supportive evidence for the assumption that gene amplification is mechanistically related to recombination.

Anti-mutagenic agents are also co-recombinogenic and can be converted into co-mutagens

In experiments using yeast without an external metabolic activation system, the hormones testosterone, beta-estradiol, and diethylstilbestrol were anti-mutagenic and co-recombinogenic. In the presence of Aroclor-induced rat liver S-9 plus cofactors (S9-mix) the same substances acted as co-mutagens and anti-recombinogens. Since an external metabolic activation system was able to convert anti-mutagens into co-mutagens, we studied whether the different metabolism of yeast and mice would lead to different effects. In whole-animal experiments using the mouse spot test, anti-mutagenic effects of vanillin (Imanishi et al., 1990), phenobarbital (Shibuya and Murota, 1984), and tannic acid (Sasaki et al., 1990) have been observed. In our present experiments with yeast, tannic acid and phenobarbital showed anti-mutagenic effects also, whereas vanillin acted as a co-mutagen. Thus, as in the case of the hormones, tannic acid and phenobarbital were anti-mutagenic and co-recombinogenic whereas vanillin was co-mutagenic as well as co-recombinogenic.

Mammary carcinogenesis induced by N-methyl-N-nitrosourea (MNU) and medroxyprogesterone acetate (MPA) in BALB/c mice

MPA induces mammary tumors in virgin BALB/c mice with an average latency of 52 weeks. In order to determine whether the simultaneous administration of a chemical carcinogen, N-methyl-N-nitrosourea (MNU), shortened the latency of MPA-induced tumors, a total of 60 virgin female BALB/c mice were treated with either MNU + MPA or MNU or MPA. The experiment lasted 7 months. The incidence and latency of mammary tumors were significantly different between the 3 groups: 15/19 (79%) in MNU + MPA-treated mice with a latency of 154 +/- 19 days; 3/20 (15%) in MNU-treated mice with a latency of 179 +/- 7 days; 0/20 (tumors only start appearing after 10 months) in MPA-treated mice. Histologically, MNU + MPA-induced tumors were similar to the few tumors observed in MNU-treated mice: most of them were type B adenocarcinomas with a high degree of necrosis and calcification. Only one of the MNU + MPA-induced tumors expressed high levels of ER and PR and proved to be MPA-responsive in further passages. All the other tumors showed low or non-detectable levels of ER and PR together with an independent pattern of tumor growth. In MNU-treated mice the only tumor that was transplanted proved to be hormone independent and had low levels of PR and ER. In both MNU and MNU + MPA treated mice lung adenocarcinomas were detected. Cystic uterine glandular hyperplasias were observed in all animals. It can be concluded that MPA and MNU potentiate their carcinogenic effect in mammary gland.

Role of tumor promotion in affecting the multi-hit nature of carcinogenesis

The assessment of risk from low-level exposure to radiation and chemicals is hindered by the basic lack of scientific understanding of the complex nature of the multiple levels of protective or synergistic interactions. Radiation and chemicals have the potential of inducing mutations, cell death and altered gene expression. The biological consequences of each of these effects is again complex, since many factors can enhance or mask the effect of a single mutation, cytotoxic or gene modulatory change. Carcinogenesis, representing but one chronic disease state, is a multi-step process, involving the clonal expansion of a single altered cell (that is, the initiation event). Radiation and chemicals appear to contribute to the initiation process by their ability to induce viable mutations. Insufficient theoretical and empirical knowledge precludes a determination of whether mutagenesis and, hence, initiation exhibit a threshold phenomenon. Because of a variety of redundancy mechanisms on the genetic and cellular levels, the physiological impact of a single dysfunctional cell is felt only after it is amplified to a large number (the promotion phase of carcinogenesis). Radiation and chemical-induced cytotoxicity, as well as noncytotoxic chemical induction of mitogenesis, can induce surviving single dysfunctional stem cells to multiply. If during this multiplication of dysfunctional cells, the initiated cells are further exposed chronically to low levels of mutagens, there is an enhanced probability of additional genetic changes. The accumulation of foci of dysfunctional cells can occur in any stem cell population of any tissue. As with mutagens, the existence of threshold levels for promoting conditions and chemicals is still not yet scientifically validated. However, specific examples of the actions of a few promoters does seem to be consistent with that idea. The concepts of initiation and promotion imply the existence of anti-initiation and antipromotion conditions. Together with genetic factors, the complex and unpredictable interactions of radiation and chemicals as initiators, anti-initiators, promoters and antipromoters, defy prospects of an easy means to predict the consequences of exposure to chronic low levels of radiation and chemicals.